2021
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
Weishaar K, Wright Z, Rosenberg M, Post G, McDaniel J, Clifford C, Phillips B, Bergman P, Randall E, Avery A, Thamm D, Hull A, Gust C, Donoghue A. Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma. Journal Of Veterinary Internal Medicine 2021, 36: 215-226. PMID: 34952995, PMCID: PMC8783351, DOI: 10.1111/jvim.16341.Peer-Reviewed Original ResearchConceptsBest overall response ratePlacebo-treated dogsProgression-free survivalOverall response rateAdverse eventsResponse rateMedian progression-free survivalCommon adverse eventsPlacebo-controlled studySerious adverse eventsNovel chemotherapy agentsClient-owned dogsTreatment of lymphomaRAB groupSignificant antitumor efficacyStudy endpointMulticentric lymphomaTreatment completionChemotherapy agentsPercent progressionSafety dataLast treatmentClinical importanceLymphomaRabacfosadine
2020
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Cawley J, Wright Z, Meleo K, Post G, Clifford C, Vickery K, Vail D, Bergman P, Thamm D. Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs. Journal Of Veterinary Internal Medicine 2020, 34: 882-889. PMID: 32064697, PMCID: PMC7096650, DOI: 10.1111/jvim.15723.Peer-Reviewed Original ResearchConceptsMedian progression-free survival timeOverall response rateComplete responseMulticentric lymphomaAdverse eventsL-asparaginaseProspective single-arm clinical trialProgression-free survival timeSingle-arm clinical trialNegative prognostic factorRelapse of lymphomaTreatment of lymphomaNovel antineoplastic agentPrognostic factorsChemotherapy protocolsClinical trialsRabacfosadineSurvival timeIU/Response rateClinical importanceLymphomaMultivariate analysisAntineoplastic agentsConcurrent use